Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis

The Effect of Aging on Infliximab Exposure and Response in Patients with Inflammatory Bowel Diseases

(2021) Wannee Kantasiripitak et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

(2021) Silje Watterdal Syversen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

New Tools for Therapeutic Drug Monitoring: Making Big Things out of Small Pieces

(2021) Erwin Dreesen   Journal of Crohns & Colitis

Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing

(2020) Dzenefa Alihodzic et al.   Frontiers in Pharmacology

Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients with Crohn's Disease

(2020) Erwin Dreesen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection

(2020) Amandine Landemaine et al.   Clinical Gastroenterology and Hepatology

Baseline Clearance of Infliximab is Associated with Requirement for Colectomy in Patients with Acute Severe Ulcerative Colitis

(2020) Robert Battat et al.   Clinical Gastroenterology and Hepatology

Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues

(2020) Zhigang Wang et al.   CURRENT OPINION IN PHARMACOLOGY

Optimising infliximab induction dosing for patients with ulcerative colitis

(2019) Erwin Dreesen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?

(2019) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

(2018) Geert D’Haens et al.   GASTROENTEROLOGY

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

(2018) Ari Brekkan et al.   AAPS Journal

Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis

(2018) Niels Vande Casteele et al.   Clinical Gastroenterology and Hepatology

American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases

(2017) Niels Vande Casteele et al.   GASTROENTEROLOGY

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

(2016) Johannan F. Brandse et al.   Clinical Gastroenterology and Hepatology

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

(2016) Klaudia Farkas et al.   Journal of Crohns & Colitis

Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

(2016) Theodora Bejan-Angoulvant et al.   Arthritis & Rheumatology

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

(2015) Maria Theresa Arias et al.   Clinical Gastroenterology and Hepatology

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

(2015) Taku Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT